Alzheimer’s: Why prevention is better than drugs – but less profitable
By Patrick Holford After 40 failed trials for drugs injecting anti-amyloid antibodies (AAAs) one, Lecanemab[i], has finally shown a modest benefit on cognitive function in those with early-stage Alzheimer’s. But they come with a terrible cost - adverse effects that include brain swelling and...
